Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H15ClN4 |
| Molecular Weight | 346.813 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4)C=C1
InChI
InChIKey=YCOYDOIWSSHVCK-UHFFFAOYSA-N
InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB04879
https://en.wikipedia.org/wiki/Vatalanib
Curator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB04879
https://en.wikipedia.org/wiki/Vatalanib
Vatalanib a potent oral tyrosine kinase inhibitor with a selective range of molecular targets, has been extensively investigated and has shown promising results in patients with solid tumors in early trials. Vatalanib selectively inhibits the tyrosine kinase domains of vascular endothelial growth factor (VEGF) receptor tyrosine kinases (important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis), platelet-derived growth factor (PDGF) receptor, and c-KIT. The adverse effects of vatalanib appear similar to those of other VEGF inhibitors. In the CONFIRM trials, the most common side effects were high blood pressure, gastrointestinal upset (diarrhea, nausea, and vomiting), fatigue, and dizziness.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 77.0 nM [IC50] | |||
| 37.0 nM [IC50] | |||
Target ID: CHEMBL1955 |
660.0 nM [IC50] | ||
Target ID: CHEMBL1936 |
730.0 nM [IC50] | ||
Target ID: CHEMBL1913 |
580.0 nM [IC50] | ||
Target ID: CHEMBL1844 |
1.4 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
Other AEs: elevated transaminases, hypertension... Other AEs: elevated transaminases (3.2%) Sources: hypertension (6.5%) hyperbilirubinemia (3.2%) Anorexia (3.2%) eructation (3.2%) Proteinuria (3.2%) Asthenia (6.5%) rash (3.2%) thrombocytopenia (3.2%) nausea (6.5%) Fatigue (6.5%) lethargy (3.2%) dizziness (3.2%) emesis (9.7%) |
1000 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: |
DLT: Lethargy, hypertension... Dose limiting toxicities: Lethargy (1 pt) Sources: hypertension (1 pt) |
1000 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy n = 35 Health Status: unhealthy Condition: myelodysplastic syndrome Sex: M+F Food Status: UNKNOWN Population Size: 35 Sources: |
DLT: Nausea, emesis... Dose limiting toxicities: Nausea (3 patients) Sources: emesis (2 patients) Anorexia (1 pt) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Anorexia | 3.2% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| Proteinuria | 3.2% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| dizziness | 3.2% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| elevated transaminases | 3.2% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| eructation | 3.2% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| hyperbilirubinemia | 3.2% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| lethargy | 3.2% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| rash | 3.2% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| thrombocytopenia | 3.2% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| Asthenia | 6.5% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| Fatigue | 6.5% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| hypertension | 6.5% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| nausea | 6.5% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| emesis | 9.7% | 750 mg 2 times / day multiple, oral (unknown) MTD Dose: 750 mg, 2 times / day Route: oral Route: multiple Dose: 750 mg, 2 times / day Sources: |
unhealthy, ADULT n = 31 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 31 Sources: |
| Lethargy | 1 pt DLT |
1000 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: |
| hypertension | 1 pt DLT |
1000 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy, ADULT n = 18 Health Status: unhealthy Condition: myeloid leukemia Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 18 Sources: |
| Anorexia | 1 pt DLT |
1000 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy n = 35 Health Status: unhealthy Condition: myelodysplastic syndrome Sex: M+F Food Status: UNKNOWN Population Size: 35 Sources: |
| emesis | 2 patients DLT |
1000 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy n = 35 Health Status: unhealthy Condition: myelodysplastic syndrome Sex: M+F Food Status: UNKNOWN Population Size: 35 Sources: |
| Nausea | 3 patients DLT |
1000 mg 2 times / day multiple, oral (unknown) Studied dose Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy n = 35 Health Status: unhealthy Condition: myelodysplastic syndrome Sex: M+F Food Status: UNKNOWN Population Size: 35 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Problems in the current target therapy of malignancies]. | 2005 |
|
| PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. | 2005 Aug |
|
| Antivascular therapy of oral tongue squamous cell carcinoma with PTK787. | 2005 Dec |
|
| Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition. | 2005 Dec |
|
| Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. | 2005 Dec |
|
| Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. | 2005 Dec 1 |
|
| Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. | 2005 Feb |
|
| Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. | 2005 Jun |
|
| The realisation of targeted antitumour therapy. | 2005 Jun |
|
| The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. | 2005 Jun 15 |
|
| Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. | 2005 Jun 15 |
|
| Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. | 2005 Jun 20 |
|
| Phacilitate Cell and Gene Therapy Forum 2005. Cell and gene therapy: a corporate perspective. 24-26 January 2005, Washington, DC, USA. | 2005 Mar |
|
| Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). | 2005 Mar |
|
| Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. | 2005 Mar 1 |
|
| Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. | 2005 May |
|
| The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. | 2005 May 9 |
|
| Update on angiogenesis inhibitors. | 2005 Nov |
|
| Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit. | 2005 Oct |
|
| Targeting multiple signal transduction pathways in lung cancer. | 2005 Sep |
|
| Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. | 2005 Sep |
|
| Clinical implications of angiogenesis in cancers. | 2006 |
|
| [Some new findings in the pathogenesis of myeloproliferative disorders and new insight into more effective treatment]. | 2006 |
|
| [Molecular targets in colon cancer]. | 2006 Apr |
|
| Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. | 2006 Aug |
|
| Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. | 2006 Dec |
|
| 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II. | 2006 Dec |
|
| Lessons from phase III clinical trials on anti-VEGF therapy for cancer. | 2006 Jan |
|
| Vascular endothelial growth factor receptor signaling is required for cardiac valve formation in zebrafish. | 2006 Jan |
|
| Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. | 2006 Jan 1 |
|
| Biological agents versus chemotherapy in the treatment of colorectal cancer. | 2006 Jul |
|
| Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. | 2006 Jul-Aug |
|
| Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. | 2006 Jun |
|
| Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. | 2006 Jun |
|
| Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. | 2006 Jun 1 |
|
| Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. | 2006 Mar 1 |
|
| Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11. | 2006 May |
|
| A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. | 2006 May 22 |
|
| 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II. | 2006 Nov |
|
| Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium. | 2006 Nov |
|
| Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. | 2006 Nov |
|
| Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. | 2006 Nov 15 |
|
| Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. | 2006 Oct |
|
| High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis. | 2006 Sep |
|
| New molecular targeted therapies in thyroid cancer. | 2006 Sep |
|
| Targeted therapy of breast cancer. | 2007 |
|
| Biological therapy update in colorectal cancer. | 2007 Apr |
|
| A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. | 2007 Apr |
|
| Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. | 2007 Feb |
|
| Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. | 2007 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Vatalanib 1,250 mg orally daily in combination with FOLFOX-4.
https://www.ncbi.nlm.nih.gov/pubmed/21464406
Vatalanib 1250 mg orally was given once daily (cohort 1) or 750-1250 mg once daily in an intra-patient dose escalating schedule (cohort 2) in 28-day cycles.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
151194
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
5DX9U76296
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
DB04879
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
212141-54-3
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
DTXSID2046919
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
m11400
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
C404768
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
100000091584
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
C1868
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL101253
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
SUB26999
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
7994
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
Vatalanib
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
90620
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY | |||
|
QQ-50
Created by
admin on Fri Dec 15 16:10:10 GMT 2023 , Edited by admin on Fri Dec 15 16:10:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
